Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that interim Phase 2 trial data for its investigational therapy istaroxime will be presented at the Heart Failure Society of America’s ...

Net Loss: BioXcel Therapeutics an operating loss of $15.9 million and a net loss of $19.2 million for the second quarter of 2025, compared to an operating loss of $17.3 million and net loss of $8.3 ...

Build your team with the Silver and Blood tier list and you'll have no trouble racing through its gothic Thread of Fate storylines.

DUBLIN, Aug. 1, 2025 /PRNewswire/ -- Mallinckrodt plc and Endo, Inc. today announced that they have completed their merger to create a global, scaled, diversified therapeutics leader. "We are ...

MILPITAS, Calif., July 30, 2025 /PRNewswire/ -- Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the official ...

Doveris’ suspense-driven tale of female empowerment is one of the most prominent titles at August’s Sanfic Industria’s WIP Iberoamericano.

Alzheimer’s Association now recommends certain blood tests for diagnosing the condition, a shift that could expand access to treatment.